Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom.

Eur J Health Econ · 2011 · PMC3197935 · PMID 20809091

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

[ 10 ], the median overall survival in these RCC patients showed a trend toward favoring ZOL (295 days for the 4-mg ZOL group versus 216 days for the placebo group) but did not achieve statistical significance compared with placebo ( P = 0.179).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.